Business Context and Reporting Period
Company: MiMedx Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2017
Event: Completion of the divestiture of its wholly-owned subsidiary, Stability Biologics, LLC ("Stability LLC").
Key Financial Metrics
This filing does not contain specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document references unaudited pro forma financial information to give effect to the divestiture, which is filed separately as Exhibit 99.2 and incorporated by reference.
Material Changes
- Asset Disposition: On September 30, 2017, the Company completed the sale of Stability LLC pursuant to a Membership Interest Purchase Agreement.
- Transaction Parties: The agreement involved the Company, Stability LLC, the stockholders of Stability Inc. (as of January 13, 2016), and Brian Martin as the stockholder representative.
- Public Announcement: A press release announcing the completion was issued on October 2, 2017 (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, management commentary on future operations, or a detailed discussion of risks and contingencies beyond the completion of the transaction. The primary focus is the legal and procedural confirmation of the divestiture.
Investor Verification Checklist
- Review Exhibit 99.2 for the unaudited pro forma condensed consolidated financial statements to understand the financial impact of the divestiture.
- Read the press release (Exhibit 99.1) dated October 2, 2017, for management's commentary on the transaction.
- Refer to the Form 8-K dated August 18, 2017 for the original terms of the Membership Interest Purchase Agreement.
- Verify the specific consideration received and any retained liabilities associated with Stability LLC in the referenced exhibits.